0RU9 Stock Chart & Stats
€754.80
€0.00(0.00%)
At close: 4:00 PM EDT
€754.80
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€754.80 - €754.80
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€9.36M
Enterprise Value€13.96
Total Cash (Recent Filing)€4.96M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
BetaN/A
Next Earnings
Nov 11, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.16
Shares Outstanding45,109,497
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.75
Price to Sales (P/S)0.00
P/FCF Ratio-0.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€2.58Price Target Upside-99.66% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.3
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Zero DebtThe absence of debt removes interest expense and refinancing obligations, giving GT Biopharma more flexibility than a similarly loss-making company with leverage. This reduces balance-sheet pressure while the business advances its clinical-stage pipeline.
Immuno-Oncology PipelineGT Biopharma is focused on a specialized immuno-oncology platform rather than a broad collection of unrelated programs. If its engineered immune-cell engaging approaches advance clinically, the platform could support multiple therapeutic opportunities over the next several quarters.
Capital Structure SimplificationRemoving inactive preferred-stock designations and reducing the authorized share base simplifies the corporate structure and may make equity administration clearer. The accompanying reverse split is intended to support continued Nasdaq trading, preserving operational access to that market.
Bears Say
No Revenue And Large LossesGT Biopharma remains pre-commercial, with no reported revenue and substantial operating and net losses. Without established product sales, the company has limited internal funding capacity and depends on clinical progress and future financing to build a sustainable earnings base.
Accelerating Cash BurnPersistent negative operating and free cash flow indicates that the business consumes significant cash to continue operations. The worsening TTM outflow increases dependence on external funding and could constrain the pace of clinical development or other investments.
Thin And Shrinking Balance SheetThe modest and volatile equity cushion provides limited protection against continuing losses, while sharply lower assets indicate reduced financial flexibility. Even without debt, this balance-sheet contraction may make funding operations and sustaining development programs more challenging.
GT Biopharma News
0RU9 FAQ
What was GT Biopharma’s price range in the past 12 months?
GT Biopharma lowest share price was €754.80 and its highest was €754.80 in the past 12 months.
What is GT Biopharma’s market cap?
GT Biopharma’s market cap is €9.36M.
When is GT Biopharma’s upcoming earnings report date?
GT Biopharma’s upcoming earnings report date is Nov 11, 2026 which is in 65 days.
How were GT Biopharma’s earnings last quarter?
GT Biopharma released its earnings results on Aug 14, 2026. The company reported -€0.103 earnings per share for the quarter, missing the consensus estimate of -€0.069 by -€0.034.
Is GT Biopharma overvalued?
According to Wall Street analysts GT Biopharma’s price is currently Overvalued.
Does GT Biopharma pay dividends?
GT Biopharma does not currently pay dividends.
What is GT Biopharma’s EPS estimate?
GT Biopharma’s EPS estimate is -0.09.
How many shares outstanding does GT Biopharma have?
GT Biopharma has 45,109,497 shares outstanding.
What happened to GT Biopharma’s price movement after its last earnings report?
GT Biopharma reported an EPS of -€0.103 in its last earnings report, missing expectations of -€0.069. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of GT Biopharma?
Currently, no hedge funds are holding shares in GB:0RU9
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
GT Biopharma
GT Biopharma, Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and bringing to market novel immuno-oncology treatments. Their innovative approach centers on a proprietary technology platform called Tri-specific Killer Engager (TriKE) fusion proteins, which are designed to harness the body's immune cells. Central to their pipeline is GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate currently undergoing Phase I/II clinical trials. This therapeutic candidate is being evaluated for its potential in treating myelodysplastic syndromes, acute myeloid leukemia that has relapsed or proven refractory to prior treatments, advanced systemic mastocytosis, and other malignancies expressing CD33. The company's research also includes GTB-3650, which is in preclinical development targeting CD33 on myeloid leukemias, and GTB-5550, another preclinical asset aimed at solid tumors that are positive for B7-H3. GT Biopharma has forged key collaborations, including a co-development agreement with Altor BioScience Corporation for the clinical advancement of a 161533 TriKE fusion protein for various cancer indications. Furthermore, they maintain a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies utilizing their TriKE technology. Founded in 1965, the company previously operated as OXIS International, Inc. before rebranding to GT Biopharma, Inc. in July 2017. Its corporate operations are based in Brisbane, California.
0RU9 Stock 12 Month Forecast
Average Price Target
€2.58
▼(-99.66% Downside)
Technical Analysis
Theriva Biologics
―
Revelation Biosciences
―
Dermata Therapeutics
―
CERo Therapeutics Holdings
―
Azitra Inc
―